SV Life Sciences Nabs $274 Million Toward Sixth Healthcare Fund

SV Life SciencesSV Life Sciences said it raised $274 million of the $400 million it hopes to put into its 6th fund for investing in healthcare companies.

The Boston-based venture capital shop said in a regulatory filing that 24 unnamed investors participated in the round, which began in May 2015.

SV Life Sciences, which has some $1.9 billion under management, invests in medical device, biotech and healthcare services companies.

Its medtech portfolio includes AcuFocusCardioFocus, CardioKinetix, Direct Flow Medical, Insulet (NSDQ:PODD), ReShape MedicalTransEnterix (NYSE:TRXC) and Ximedica.

The VC firm raised a $523 million fund back in 2010.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply